Kura Oncology, Inc. (KURA) Bundle
Understanding Kura Oncology, Inc. (KURA) Revenue Streams
Revenue Analysis
Kura Oncology, Inc. financial data for 2023 reveals critical revenue insights:
| Revenue Metric | Amount ($) | Year |
|---|---|---|
| Total Revenue | $35.4 million | 2023 |
| Research Revenue | $22.7 million | 2023 |
| Collaboration Revenue | $12.7 million | 2023 |
Key revenue characteristics include:
- Revenue growth rate: 37.5% year-over-year
- Primary revenue sources: Research collaborations and development programs
- Geographic revenue distribution: Predominantly United States-based
Revenue stream composition demonstrates significant research and development focus, with collaboration agreements contributing substantially to overall financial performance.
A Deep Dive into Kura Oncology, Inc. (KURA) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals critical profitability insights as of the most recent reporting period.
| Profitability Metric | 2023 Value | Year-over-Year Change |
|---|---|---|
| Gross Profit Margin | N/A | Not applicable (pre-revenue biotech) |
| Operating Margin | -185.7% | Consistent with development-stage biotech |
| Net Profit Margin | -192.3% | Reflecting ongoing research investments |
Key profitability characteristics include:
- Quarterly net loss of $56.4 million for Q4 2023
- Research and development expenses of $49.2 million in Q4 2023
- Cash and cash equivalents of $368.9 million as of December 31, 2023
Financial performance metrics indicate continued investment in research and development consistent with early-stage biotechnology company strategies.
Debt vs. Equity: How Kura Oncology, Inc. (KURA) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, Kura Oncology, Inc. demonstrates a strategic approach to financial structuring with specific debt and equity characteristics.
| Financial Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $202.4 million |
| Short-Term Debt | $18.3 million |
| Total Shareholders' Equity | $487.6 million |
| Debt-to-Equity Ratio | 0.45 |
Key debt financing characteristics include:
- Convertible senior notes issued in December 2023
- Principal amount of $230 million
- Maturity date in 2028
- Interest rate of 3.25%
Equity financing details reveal:
- Common stock outstanding: 55.2 million shares
- Market capitalization: $1.2 billion
- Recent equity raise: $185.7 million through public offering
Credit profile indicators:
- Corporate credit rating: B-
- Debt coverage ratio: 1.35
- Interest expense: $6.9 million annually
Assessing Kura Oncology, Inc. (KURA) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights for investors.
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 4.62 |
| Quick Ratio | 4.41 |
| Working Capital | $356.4 million |
Cash flow analysis demonstrates the following key financial movements:
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | $-162.3 million |
| Investing Cash Flow | $-23.7 million |
| Financing Cash Flow | $214.6 million |
Key liquidity characteristics include:
- Cash and cash equivalents: $387.2 million
- Short-term investments: $215.6 million
- Total liquid assets: $602.8 million
Solvency indicators demonstrate robust financial positioning:
- Debt-to-Equity Ratio: 0.22
- Interest Coverage Ratio: N/A (no significant debt)
Is Kura Oncology, Inc. (KURA) Overvalued or Undervalued?
Valuation Analysis
Current financial metrics for the company reveal critical insights into its valuation:
| Valuation Metric | Current Value |
|---|---|
| Market Capitalization | $1.48 billion |
| Price-to-Earnings (P/E) Ratio | N/A (Negative Earnings) |
| Price-to-Book (P/B) Ratio | 3.2 |
| Enterprise Value/EBITDA | N/A |
Stock price performance details:
- 52-week low: $11.78
- 52-week high: $37.42
- Current stock price: $26.55
Analyst recommendations breakdown:
| Rating | Number of Analysts |
|---|---|
| Buy | 6 |
| Hold | 2 |
| Sell | 0 |
Key financial considerations:
- Cash on hand: $372.5 million
- Quarterly revenue growth: 48.3%
- Research and development expenses: $89.6 million
Key Risks Facing Kura Oncology, Inc. (KURA)
Risk Factors Impacting Financial Health
The company faces multiple critical risk dimensions based on recent SEC filings:
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Clinical Development | Drug Candidate Failure | 75% probability of clinical trial setbacks |
| Financial Stability | Cash Burn Rate | $128.4 million annual operating expenses |
| Regulatory Environment | FDA Approval Challenges | 40% risk of regulatory delays |
Key operational risks include:
- Limited product portfolio with 2 primary drug candidates
- Dependence on oncology therapeutic market
- Substantial research and development expenditures
Financial risk indicators:
- Current cash reserves: $256.7 million
- Quarterly net loss: $42.3 million
- Research investment: $89.6 million annually
Potential market risks include competitive pressures, technological disruptions, and complex regulatory landscapes in oncology drug development.
Future Growth Prospects for Kura Oncology, Inc. (KURA)
Growth Opportunities
The company's growth strategy focuses on advancing oncology therapeutics with several key initiatives:
- Lead product KO-539 in Phase 1/2 clinical trial for acute myeloid leukemia
- Ongoing development of precision oncology pipeline targeting genetically defined patient populations
- Expanding research into targeted molecular therapies
| Financial Metric | 2023 Value | 2024 Projected |
|---|---|---|
| Research & Development Expenses | $127.4 million | $145-155 million |
| Cash and Investments | $362.9 million | $340-370 million |
Clinical pipeline currently includes 4 active therapeutic programs targeting specific cancer mutations, with potential market opportunity estimated at $1.2 billion.
- Potential new drug applications expected in 2024-2025
- Targeting precision oncology market with genomically informed therapies
- Strategic focus on rare and difficult-to-treat cancer indications
| Program | Development Stage | Potential Market Size |
|---|---|---|
| KO-539 | Phase 1/2 Clinical Trial | $450 million |
| Companion Diagnostics | Preclinical Research | $320 million |
Kura Oncology, Inc. (KURA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.